Targeting DDR2 enhances tumor response to anti–PD-1 immunotherapyMegan M. Tu, Dan Theodorescu, Elizabeth Saravia et al.|Science Advances|2019Cited by 126
Development of BET Inhibitors as Potential Treatments for Cancer: Optimization of Pharmacokinetic PropertiesMatthew D. Hill, Andrew P. Degnan, Haiquan Fang et al.|ACS Medicinal Chemistry Letters|2022Cited by 10